Page last updated: 2024-11-06

ciclazindol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Ciclazindol is a tricyclic antidepressant that acts as a potent and selective inhibitor of serotonin reuptake. It was first synthesized in the 1970s and has been studied for its potential therapeutic effects in various conditions, including depression, anxiety, and pain. Ciclazindol's unique pharmacological profile makes it a promising candidate for the development of novel antidepressant medications, and it is currently undergoing clinical trials for its efficacy and safety. It has been reported to exhibit anti-inflammatory properties and may have potential applications in the treatment of inflammatory bowel disease. However, further research is needed to fully understand its therapeutic potential and potential side effects.'

ciclazindol: highly selective inhibitor of noradrenaline uptake; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID37825
CHEMBL ID1192491
SCHEMBL ID122673
MeSH IDM0055181

Synonyms (26)

Synonym
10-(3-chlorophenyl)-2,3,4,10-tetrahydropyrimido[1,2-a]indol-10-ol
10-(3-chlorophenyl)-3,4-dihydro-2h-pyrimido[1,2-a]indol-10-ol
wy-23409
D03486
ciclazindol (usan/inn)
37751-39-6
nsc300923
ciclazindol
CHEMBL1192491
ciclazindolum
10-(m-chlorophenyl)-2,3,4,10-tetrahydropyrimido(1,2-a)indol-10-ol
y3i9520j7p ,
ciclazindolum [inn-latin]
wy 23,409
wy-23,409
unii-y3i9520j7p
ciclazindol [usan:inn:ban]
pyrimido(1,2-a)indol-10-ol, 10-(3-chlorophenyl)-2,3,4,10-tetrahydro-
SCHEMBL122673
ciclazindol [usan]
ciclazindol [inn]
10-(m-chlorophenyl)-2,3,4,10-tetrahydropyrimido[1,2-a]indol-10-ol
10-(3-chlorophenyl)-2,3,4,10-tetrahydropyrimido[1,2-a]indol -10-ol
VKQDZNZTPGLGFD-UHFFFAOYSA-N
Q5119442
DTXSID50865883

Research Excerpts

Dosage Studied

Daily dosing with ciclazindol for 3 weeks did not appear to induce the enzymes of its own metabolism. In the dosage used (100 mg/day) cicLazindols was observed to be a peripheral Na-reuptake blocker with no significant effect on the postsynaptic alpha-receptors.

ExcerptRelevanceReference
" In the dosage used (100 mg/day) ciclazindol was observed to be a peripheral Na-reuptake blocker with no significant effect on the postsynaptic alpha-receptors."( Antidepressant activity and pharmacological interactions of ciclazindol.
Bailey, J; Coppen, A; Ghose, K; Rama Rao, VA, 1978
)
0.78
" The author concludes that ciclazindol offers promise and merits further study using higher dosage levels once its full safety trials have been completed."( A controlled comparative trial of a new antidepressant, ciclazindol.
Levine, S, 1979
)
0.8
" Daily dosing with ciclazindol for 3 weeks did not appear to induce the enzymes of its own metabolism."( The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers.
Coleman, AJ; Franklin, RA; Southgate, PJ; Swaisland, AJ, 1977
)
0.89
" Relative potencies of a number of the most active compounds were defined by three-point dose-response studies."( Oral hypoglycemic agents. Pyrimido[1,2-a]indoles and related compounds.
Black, RM; Cliffe, IA; Lien, EL; Mansell, HL; Steiner, KE; Todd, RS; White, AC, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (60.00)18.7374
1990's8 (32.00)18.2507
2000's2 (8.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (23.08%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (73.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]